LLY Factor-Based Stock Analysis

Validea's guru fundamental report indicates that Eli Lilly (LLY) receives a 77% rating based on their P/B Growth Investor model, which is based on the strategy of Partha Mohanram and favors low book-to-market stocks with sustained growth characteristics; the model gives LLY high marks for book/market ratio, return on assets, and sales variance, but flags the stock for capital expenditures to assets and research and development to assets.

Analysis

Eli Lilly and Co. (LLY) has been evaluated by Validea's P/B Growth Investor model, based on Partha Mohanram's strategy, achieving a score of 77%. This model favors low book-to-market stocks with attributes of sustained future growth, and LLY's score approaches the 80% threshold that typically signals model interest. The company, a large-cap growth stock in the Biotechnology & Drugs sector, passed key fundamental tests including book/market ratio, return on assets, cash flow from operations to assets, stability in return on assets and sales variance, and advertising to assets, indicative of robust financial health and growth drivers. Conversely, LLY failed criteria related to capital expenditures to assets and research and development to assets. These high investment levels, while potentially weighing on current asset-based ratios, are common for biotech firms focused on innovation and future product pipelines. The overall sentiment towards LLY is moderately positive, with a specific ticker sentiment score of 0.6, supporting the model's generally constructive, albeit not strongly conclusive, assessment.

Key Decisions for Investors

• Consider Eli Lilly's current valuation and growth profile, noting its 77% score on the Partha Mohanram P/B Growth model indicates positive attributes but falls just short of a formal 'interest' signal by this specific quantitative strategy.
• Investigate the flagged high levels of capital expenditures and R&D relative to assets to determine if these are strategically sound investments for long-term value creation in the biotechnology industry, or if they pose undue risk to asset efficiency.
• Monitor the productivity of LLY's significant investments and its ability to maintain strong performance in areas like return on assets and sales growth, which are key underpinnings of the growth thesis.